PVCT Stock, Provectus Biopharmaceuticals Inc Information

Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer and liver cancer. Provectus investigational oncology drug, PV , is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH , its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase trials of PV as a therapy for metastatic melanoma, and of PH as a topical treatment for psoriasis. In addition, Provectus has begun a Phase trial as a therapy for metastatic melanoma. Information about these and the Company s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company s website at www.provectusbio.com.